Cas No.: | 152239-46-8 |
Chemical Name: | Urea,N-(1-methyl-1H-indol-5-yl)-N'-(3-methyl-5-isothiazolyl)- |
Synonyms: | Urea,N-(1-methyl-1H-indol-5-yl)-N'-(3-methyl-5-isothiazolyl)-;1-(1-methylindol-5-yl)-3-(3-methyl-1,2-thiazol-5-yl)urea;SB 204741;Lopac-S-0693;N-(1-Methyl-1H-5-indolyl)-N'-(3-methyl-5-isothiazolyl)urea;N-(1-Methyl-1H-indolyl-5-yl)-N''-(3-Methyl-5-isothiazolyl)urea;Tocris-1372;N-(1-Methyl-1H-5-indolyl)-N′-(3-methyl-5-isothiazolyl)urea;N-(1-METHYL-1H-5-INDOLYL)-N'-(3-METHYL-5-ISOTHIAZOLYL)UREA;1-(1-Methyl-1H-indol-5-yl)-3-(3-Methylisothiazol-5-yl)urea;N-(1-METHYL-1H-INDOLYL-5-YL)-N''-(3-METHYL-5-ISOTHIAZOLYL)UREA |
SMILES: | CN1C2C(=CC(NC(NC3SN=C(C)C=3)=O)=CC=2)C=C1 |
Formula: | C14H14N4Os |
M.Wt: | 286.352160930634 |
Purity: | >98% |
Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Description: | SB 204741 is a selective and high affinity 5-HT2B antagonist with a pKi value of 7.1[1]. |
Target: | human 5-HT2B Receptor:7.1 (pKi) |
In Vivo: | SB-204741 (0.25~1.0 mg/kg; i.p.) induces myocardial remodeling and dose dependently improves hemodynamic and ventricular functions following isoproterenol-induced myocardial injury[1]. SB-204741 bolsters endogenous anti-oxidant enzymes activities, improves cardiac injury markers, NO level and lipid peroxidation level and attenuates TNFα level in isoproterenol-induced myocardial remodeling in rats. SB-204741 (0.5 and 1.0 mg/kg/day) pre-treatment for 28 days significantly amplifies NO level and GSH and SOD activities and attenuates TBARS level following isoproterenol-induced myocardial remodeling. SB-204741 inhibits inflammatory protein expression, upregulates autophagy and HSPs protein expressions in isoproterenol-induced myocardial remodeling in rats. SB-204741 improves myocardial architecture in isoproterenol-induced myocardial remodeling in rats[1]. Animal Model: Rats[1] Dosage: 0.25~1.0 mg/kg Administration: I.p. Result: Induced myocardial remodeling. |
In Vitro: | The most selective 5-HT2B receptor ligand to be tested is SB 204741 with approximately 20 fold selectivity for the human 5-HT2B receptor as compared to the human 5-HT2C receptor[1]. |
References: | [1]. Bonhaus DW, et al. The pharmacology and distribution of human 5-hydroxytryptamine2B (5-HT2B) receptor gene products: comparison with 5-HT2A and 5-HT2C receptors. Br J Pharmacol. 1995;115(4):622-628. [2]. Bharti S, et al. 5-HT2B receptor blockade attenuates β-adrenergic receptor-stimulated myocardial remodeling in rats via inhibiting apoptosis: role of MAPKs and HSPs. Apoptosis. 2015;20(4):455-465. |